There were 1.1% of participants who died because of serious adverse reactions.
This was 14 out of 1,302 participants. These participants were:
X 2 out of 152 participants (1.3%) who got durvalumab and the lower dose of
tremelimumab
X 9 out of 388 participants (2.3%) who got durvalumab and the higher dose
of tremelimumab
X 3 out of 374 participants (0.8%) who got standard treatment
None of the participants who got durvalumab alone died because of serious
adverse reactions.
17 | Clinical Trial Results